Recently, the tumor resistance to several antitumor agents (e.g. cisplatin, oxaliplatin, carboplatin, doxorubicin, etoposide, rapamycin, everolimus, alpelisib, pictilisib, and AZD8055) was related to elevated and sustained activation of the PI3K/mTOR signaling pathway (148). This evidence concerns the gene MTOR and neoplasm.